Medical Fund in Poland

Due to the Act on the Medical Fund in force we looked into registration drugs in European Medicines Agency (#EMA) to see which products may be included in the upcoming high clinical value drugs list by #AOTMiT.

From 2017 to the end of July 2021, 268 new products were registered by EMA, 107 of which are orphan drugs (40%). Around 85% of these drugs may be assessed by AOTMiT, rest of them – 15% are already being reimbursed in Poland. Out of these 85% drugs – 44 are oncological drugs (including 18 oncological orphan drugs (41%)), and 191 non-oncological drugs (including 48 non-oncological orphan drugs (25%)).

According to the ATC classification, the largest group of drugs (TOP 3) are antineoplastic and immunomodulating agents (ATC: L, 59 products), antiinfectives for systemic use (ATC: J, 36 products) and nervous system drugs (ATC N, 30 products).